fintols

Novo Nordisk vs Sanofi (NVO vs SAN.PA)

Novo Nordisk trades at 10.0x earnings vs 24.3x for Sanofi; Sanofi grows sales faster (+15.7% vs +5.6%). Margins, debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Novo Nordisk looks cheaper on P/E: 10.0x against 24.3x for Sanofi. Sanofi grows faster: sales +15.7% against +5.6% for Novo Nordisk in the latest quarter. Novo Nordisk has the better net margin: 33.9% against 8.2% for Sanofi.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Novo Nordisk freeAnalyze Sanofi free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Sanofi is the more expensive of the two: it trades at 24.3x its annual earnings against 10.0x for Novo Nordisk. Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. What helps read that gap: Sanofi sales +15.7% against +5.6% for Novo Nordisk in the latest quarter; net margin 8.2% against 33.9%; net debt for Sanofi: 0.9x EBITDA against 0.5x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Novo Nordisk (NVO) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Novo Nordisk and Sanofi side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Novo Nordisk or Sanofi.

Novo Nordisk vs Sanofi: the figures

FigureNovo NordiskSanofi
Share price$39.43 (November 18, 2026)€84.08 (November 19, 2026)
Market cap$173.8 billion€100.9 billion
P/E (TTM)10.0x24.3x
Forward P/E1.7x8.8x
Revenue growth (quarter)+5.6%+15.7%
Net margin (TTM)33.9%8.2%
Net debt / EBITDA0.5x0.9x
Dividend yield4.56%4.76%
Beta0.370.26

Novo Nordisk and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Novo Nordisk or Sanofi figure is not available, and we never estimate it.

3 key differences between Novo Nordisk and Sanofi

  1. Valuation: Sanofi trades at 24.3x its annual earnings and Novo Nordisk at 10.0x; the market pays more for each dollar of Sanofi profit, usually because it expects more growth.
  2. Profitability: for every 100 of sales, Novo Nordisk keeps 33.9 as net profit and Sanofi keeps 8.2.
  3. Growth: Sanofi grew sales +15.7% year on year in its latest quarter, against +5.6% for Novo Nordisk.

Novo Nordisk or Sanofi: which fits your profile

Neither Novo Nordisk nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Novo Nordisk or Sanofi?

Of the 6 comparable figures in the table, Novo Nordisk stands out on 3 (net margin, lower P/E and less debt over EBITDA) and Sanofi stands out on 3 (sales growth, dividend yield and lower volatility (beta)). That does not name a winner between Novo Nordisk and Sanofi: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Novo Nordisk vs Sanofi (NVO vs SAN.PA)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze NVO free